Generic Name and Formulations:
Ketoconazole 2%; topical gel (anhydrous).
Indications for XOLEGEL:
Topical treatment of seborrheic dermatitis in immunocompetent patients.
Apply a thin layer to affected area(s) once daily for 2 weeks. Wash hands before and after use. Do not wash treated areas for at least 3 hours after application. Wait at least 20 mins before applying cosmetics, sunscreen, etc.
Avoid eyes, lips, mucous membranes. If irritation occurs or if disease worsens, then the use of the medication should be discontinued. Product is flammable (avoid open flames, smoking while applying). Pregnancy (Cat.C). Nursing mothers.
Application site burning, headache.
Gel—45g; Xolegel Duo—1 kit (15g gel + 4oz Xolex shampoo [zinc pyrithione 1%]); or (15g gel + 1.7oz Head & Shoulders shampoo [zinc pyrithione 1%])
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|